COMP <GO>
AMRX vs IONS // OPERATING MARGIN
Amneal Pharmaceuticals Inc. (NASDAQ) VS. Ionis Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: AMRX 8
— IONS 4
▲ OPERATING MARGIN LEADER: AMRX
LAST: $20.44 (-4.97%) • MKT CAP: $7.12B
operating-margins
13.10%
LAST: $41.24 (-5.24%) • MKT CAP: $6.85B
operating-margins
-40.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMRX VS. IONS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMRX | IONS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.90% | 96.00% | -59.10 | IONS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.10% | -20.90% | +35.00 | AMRX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.4x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 3.63% | -4.34% | +7.97 | AMRX | /fcf-yield <GO> |
| Operating Margin ACTIVE | 13.10% | -40.40% | +53.50 | AMRX | /operating-margins <GO> |
| Net Profit Margin | 2.40% | -40.40% | +42.80 | AMRX | /net-margins <GO> |
| Revenue Growth (YoY) | 8.00% | 33.80% | -25.80 | IONS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.83 | 1.08 | +2.75 | AMRX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 5/9 | +4.00 | AMRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.1 | 36.2 | +14.90 | AMRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.09 | -0.01 | IONS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 96.0x | 22.0x | +74.00 | IONS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.12B | $6.85B | $265.7M | AMRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMRX REV | IONS REV | AMRX GROSS % | IONS GROSS % | AMRX FCF | IONS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.02B | $943.7M | 36.9% | 98.3% | $269.9M | -$320.0M |
| FY 2024 | $2.79B | $705.1M | 36.5% | 98.4% | $243.2M | -$546.2M |
| FY 2023 | $2.39B | $787.6M | — | — | $237.9M | -$343.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMRX // BETA 1.08
IONS // BETA 1.09